金吾财讯 | 博安生物(06955)尾盘一度涨超188%，截至发稿，仍涨超111%，报17.4港元，成交额2.34亿港元。消息面上，日前，博安生物公布2024年度财报，收入7.26亿人民币(下同)，按年增加17.5%。录得纯利7,319万元，相较上年度亏损1.19亿元，亏转盈；每股盈利14分。不派末期息。华安证券近日研报表示，公司通过多元化的对外合作策略显著提升了研发效率、生产质量及商业化能力，形成了全产业链的协同优势。商业化领域，公司采取“授权+联合推广”模式，将地舒单抗(博优倍)在中国大陆的推广权授予正大制药青岛，将阿柏西普(博优景)在中国大陆的推广权授予欧康维视，借助两家合作伙伴分别在骨松和眼科领域的终端覆盖能力快速放量；新兴市场方面，公司与多个南美和东南亚合作伙伴签署授权协议，利用本地资源推动产品在当地市场的注册与销售。研发端，公司授予健康元开发和商业化长效IL-4Rα单抗BA2101的呼吸系统适应症权利，依托健康元在呼吸领域的市场资源加速项目推进多元化对外合作帮助公司加速创新药与生物类似药全球化布局，形成“研发-生产-销售”闭环的竞争优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.